- Home
- CMMB vs FLGC Comparison
CMMB vs FLGC Comparison
Compare CMMB & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- FLGC
- Stock Information
- Founded
- CMMB 2004
- FLGC 2019
- Country
- CMMB Israel
- FLGC United States
- Employees
- CMMB N/A
- FLGC N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- FLGC Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- FLGC Health Care
- Exchange
- CMMB Nasdaq
- FLGC Nasdaq
- Market Cap
- CMMB 27.0M
- FLGC 26.5M
- IPO Year
- CMMB N/A
- FLGC 2021
- Fundamental
- Price
- CMMB $1.60
- FLGC $1.31
- Analyst Decision
- CMMB Strong Buy
- FLGC Strong Buy
- Analyst Count
- CMMB 3
- FLGC 3
- Target Price
- CMMB $7.33
- FLGC $6.50
- AVG Volume (30 Days)
- CMMB 119.1K
- FLGC 515.7K
- Earning Date
- CMMB 11-14-2024
- FLGC 11-13-2024
- Dividend Yield
- CMMB N/A
- FLGC N/A
- EPS Growth
- CMMB N/A
- FLGC N/A
- EPS
- CMMB N/A
- FLGC N/A
- Revenue
- CMMB N/A
- FLGC $64,154,000.00
- Revenue This Year
- CMMB N/A
- FLGC N/A
- Revenue Next Year
- CMMB N/A
- FLGC $19.90
- P/E Ratio
- CMMB N/A
- FLGC N/A
- Revenue Growth
- CMMB N/A
- FLGC N/A
- 52 Week Low
- CMMB $0.42
- FLGC $0.75
- 52 Week High
- CMMB $2.55
- FLGC $2.93
- Technical
- Relative Strength Index (RSI)
- CMMB 52.53
- FLGC 47.10
- Support Level
- CMMB $1.54
- FLGC $1.19
- Resistance Level
- CMMB $1.73
- FLGC $1.38
- Average True Range (ATR)
- CMMB 0.16
- FLGC 0.14
- MACD
- CMMB 0.01
- FLGC -0.01
- Stochastic Oscillator
- CMMB 45.45
- FLGC 39.05
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.